spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Lamivudine 

 HSMN NewsFeed - 28 Mar 2018
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Biopharmaceuticals HIV/AIDS FDA Product Launch
 HSMN NewsFeed - 2 Mar 2018
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
Biopharmaceuticals HIV/AIDS Product Launch
 HSMN NewsFeed - 6 Oct 2014
Mylan Launches Generic Combivir
Biopharmaceuticals Generics HIV/AIDS Product Launch
 HSMN NewsFeed - 22 Nov 2013
Tivicay(R) (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 23 Feb 2012
Mylan Receives Tentative FDA Approval Through PEPFAR for Pediatric HIV/AIDS Therapy
Biopharmaceuticals Generics HIV/AIDS FDA
 HSMN NewsFeed - 20 Sep 2011
Mylan's Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 Oct 2009
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry for Use in Patients Starting HIV Therapy for the First Time
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 16 Sep 2009
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 15 Sep 2009
European Union Commission Approves Expanded Use of ISENTRESS(R) (raltegravir), from MSD, in Adult Patients with HIV-1 Infection
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 29 Aug 2008
Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude(R) (entecavir) as a Treatment Option for Chronic Hepatitis B
Biopharmaceuticals
 HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Aug 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Biopharmaceuticals HIV/AIDS Distribution
 HSMN NewsFeed - 25 Apr 2008
European Commission Approves Viread(R) for Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Mar 2008
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 2 Nov 2007
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Biopharmaceuticals
 HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Oct 2007
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 17 Oct 2007
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 25 Jul 2007
New Head-to-Head Study Comparing LEXIVA(R) and Atazanavir Show Similar Efficacy and Lipid Changes
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 25 Jul 2007
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 25 Jun 2007
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2007
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Apr 2007
Four-Year Data Demonstrate Continued Low Incidence of BARACLUDE(R) (entecavir) Resistance in Nucleoside-naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2007
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2007
SEBIVO(R) (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B
Biopharmacetuicals Regulatory
 HSMN NewsFeed - 23 Feb 2007
SEBIVO(R) (telbivudine) Recommended for Approval in European Union as a new Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Feb 2007
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
Biopharmacetuicals HIV/AIDS
 HSMN NewsFeed - 15 Dec 2006
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 30 Oct 2006
Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2006
BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2006
TYZEKA(TM) (telbivudine) Approved by U.S. Food and Drug Administration (FDA) as a New Treatment for Patients with Chronic Hepatitis B
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Oct 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
New Data Reinforce Efficacy of TRIZIVIR(R) Alone in Treatment-Naive HIV Patients with Low Viral Load
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 21 Sep 2006
Telbivudine Approved in Switzerland for Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 23 May 2006
96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 90

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 90 additional stories matching:
Lamivudine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.